Mg. Hunter et al., BB-10010 - AN ACTIVE VARIANT OF HUMAN MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA WITH IMPROVED PHARMACEUTICAL PROPERTIES, Blood, 86(12), 1995, pp. 4400-4408
The stem cell inhibitor, macrophage inflammatory protein-1 alpha (MIP-
1 alpha) or LD78, protects multipotent hematopoietic progenitors in mu
rine models from the cytotoxic effects of chemotherapy. Clinical use o
f human MIP-1 alpha during chemotherapy could therefore lead to faster
hematologic recovery and may allow dose intensification. We have also
shown that human MIP-1 alpha causes the rapid mobilization of hematop
oietic cells, suggesting an additional clinical use in peripheral bloo
d stem cell transplantation. However, the clinical evaluation of human
MIP-1 alpha is complicated by its tendency to associate and form high
molecular weight polymers. We have produced a variant of rhMIP-1 alph
a, BE-10010, carrying a single amino acid substitution of Asp26 > Ala,
with a reduced tendency to form large polymers at physiologic pH and
ionic strength. This greatly increases its solubility, facilitating it
s production and clinical formulation. We confirmed the potency of BE-
10010 as a human MIP-1 alpha-like agonist in receptor binding, calcium
mobilization, inhibition of colony formation, and thymidine suicide a
ssays. The myeloprotective activity of BE-10010 was shown in a murine
model of repeated chemotherapy using hydroxyurea. BE-10010 is therefor
e an ideal variant with which to evaluate the therapeutic potential of
recombinant human MIP-1 alpha. (C) 1995 by The American Society of He
matology.